Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research



 
Contact Us
 
Connect With Us!
 
 

News Release

FOR RELEASE
April 2, 2014

New Vision Disease Finding Underscores
Importance of Innovative Basic Research

BrightFocus-Funded Research Yields Potential for New Treatments

Clarksburg, MD—A study published today in Science Translational Medicine sheds dramatic new light on a component of the immune system that can help prevent, not cause, damage to blood vessels in the eye. This is an example of the benefits of funding basic researchers who want to pursue innovative—even controversial—avenues of discovery, say officials at BrightFocus Foundation.

BrightFocus, a non-profit organization, helped fund research by Sarah Doyle, Ph.D., Matthew Campbell, Ph.D., Peter Humphries, Ph.D., and others at Trinity College in Dublin, on the role of component IL-18 in macular degeneration. The scientists found that IL-18—typically linked to inflammation, and thus seen as a cause of abnormal blood vessel growth in this eye disease—actually helped suppress damage to blood vessels behind the eye’s retina.

“Supporting innovative research to solve the riddles of age-related macular degeneration (AMD) is the only way we’re going to stop or slow this disease,” said BrightFocus President and CEO Stacy Pagos Haller. “We have a long history of identifying, and funding early, the most promising research and researchers, including out-of-the-box thinkers willing to pursue novel areas of discovery.”

BrightFocus support was directed to earlier studies by the same authors and the organization is currently funding lead author Doyle for related research. These scientists hypothesized that, while inflammation clearly contributes to AMD, macular degeneration therapy might pinpoint very specific locations and effects of inflammation, and develop a targeted IL-18 treatment.

 “Today’s news represents an exciting leap forward on how best to use our body’s natural defenses to shield us from the effects of AMD,” noted Guy Eakin, Ph.D., BrightFocus Vice President for Scientific Affairs.

The researchers also showed that in an animal model, IL-18 could be administered in a non-invasive way by traditional injection, an easier method than the eye injections currently used in treatments.

Macular degeneration, which can interfere with straight-ahead (central) vision, is a leading cause of irreversible vision loss throughout the world.

# # #

ABOUT BRIGHTFOCUS FOUNDATION
BrightFocus Foundation (www.brightfocus.org) is a nonprofit organization dedicated to advancing brain and eye health, by funding research worldwide on macular degeneration, glaucoma, and Alzheimer’s disease.  BrightFocus also provides the public with information about these diseases, including risk factors, current treatments, and coping strategies.

CONTACT:

Michael Buckley, Vice President of Public Affairs
BrightFocus Foundation
Phone: (301) 556-9370; Email: mbuckley@brightfocus.org

Alice L. Kirkman, Marketing and Communications Manager
BrightFocus Foundation
Phone: (301) 556-9349; Email: akirkman@brightfocus.org

Last Review: 04/02/14


::

]]

Twitter Facebook Shop for a Cause YouTube Pinterest Google+